Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Intravenous Adenosine Infusion With Regadenoson Bolus for Inducing Maximal Coronary Hyperemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* male or female patients greater than 18 years old (If female, pt. must be post-menopausal, surgically sterile, or be non-pregnant as determined by a negative urine or serum beta human chorionic gonadotropin (B-HCG) pregnancy test within 24 hours prior to enrollment.~* Provided written consent approved by Institutional Review Board and provided Health Insurance Portability and Accountability Act (HIPAA) authorization~* Have at least one coronary stenosis (greater or equal to 40% but less than 70\& narrowing by visual inspection) and technically accessible coronary artery into which the pressure wire may be introduced.~Exclusion Criteria:~* ST elevation myocardial infarction~* Cardiogenic shock~* Pregnancy~* Total vessel occlusion~* Extremely tortuous coronary arteries~* Second and third degree heart block without pacemaker~* Severe chronic obstructive pulmonary disease and active bronchospasm~* Less than age 18 years~* Have received theophylline, aminophylline, pentoxifylline or dipyridamole within 12 hours of FFR measurement.~* Has severe 3 vessel disease defined by \>80% luminal narrowing by visual inspection~* Known hypersensitivity to adenosine or regadenoson~* Recent uncontrolled ventricular arrhythmia~* History of greater than Type I atrioventricular block, symptomatic resting bradycardia, sick sinus syndrome (without permanent pacemaker)~* History of heart transplantation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Adenosine then Regadenoson (Type: EXPERIMENTAL): Adenosine infusion will be compared to Regadenoson for efficacy and safety/side effects. Arterial blood pressure, coronary pressure, heart rate, oxygen saturation and coronary flow, FFR, and coronary flow velocity will be assessed. Safety will be assessed by monitoring for any side effects such as chest pain, headache, flushing, nausea, or arrhythmias. Adenosine infusion will be administered at 140 mcg/kg for 2 minutes and once mean coronary flow velocity returns to within 15% of pre-dose value, Regadenoson IV bolus 0.4 mg/5 ml will be administered followed by a 5 cc normal saline flush.

Based on this trial design, predict the completion outcome and termination type (if applicable).